Damora Therapeutics, Inc. Common Stock (DMRA) Stock Price, News & Analysis

Company Overview

Galecto Inc. is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders. In addition, Galecto is advancing a LOXL2 inhibitor, GB2064, in preclinical studies aimed at addressing unmet needs in hepatic and systemic fibrosis. These molecules leverage targeted delivery and selective inhibition strategies to modulate the fibrotic cascade and the tumor microenvironment.

Founded in 2012, Galecto is headquartered in Copenhagen, Denmark, with research and development operations in Cambridge, Massachusetts. The company’s leadership team brings together expertise in molecular biology, medicinal chemistry and clinical development, with board members and executives drawn from both academia and the pharmaceutical industry. Galecto collaborates with academic centers and industry partners to advance its pipeline and explore additional indications for its proprietary inhibitors.

Key Stats

• Today's Range: $24.77 to $25.96
• 50-Day Range: $18.14 to $32.30
• 52-Week Range: $2.45 to $38.33
• Volume: 142,526 shs
• Average Volume: 238,866 shs
• Market Capitalization: $1.50 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.40
• Consensus Rating: Moderate Buy

Damora Therapeutics, Inc. Common Stock Stock Analysis - MarketRank™

Damora Therapeutics, Inc. Common Stock scored higher than 52% of companies evaluated by MarketBeat, and ranked 387th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Damora Therapeutics, Inc. Common Stock has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Damora Therapeutics, Inc. Common Stock has a consensus price target of $43.40, representing about 74.5% upside from its current price of $24.87.

Amount of Analyst Coverage

Damora Therapeutics, Inc. Common Stock has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Damora Therapeutics, Inc. Common Stock are expected to decrease in the coming year, from ($0.95) to ($1.36) per share.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.07% of the float of Damora Therapeutics, Inc. Common Stock has been sold short.

Short Interest Ratio / Days to Cover

Damora Therapeutics, Inc. Common Stock has a short interest ratio ("days to cover") of 4.72.

Change versus previous month

Short interest in Damora Therapeutics, Inc. Common Stock has recently increased by 34.98%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Damora Therapeutics, Inc. Common Stock does not currently pay a dividend.

Dividend Growth

Damora Therapeutics, Inc. Common Stock does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.02

News Sentiment

Damora Therapeutics, Inc. Common Stock has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Damora Therapeutics, Inc. Common Stock this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Damora Therapeutics, Inc. Common Stock to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Damora Therapeutics, Inc. Common Stock insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.46% of the stock of Damora Therapeutics, Inc. Common Stock is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

14.20% of the stock of Damora Therapeutics, Inc. Common Stock is held by institutions.

DMRA Stock Analysis - Frequently Asked Questions

How have DMRA shares performed this year?

Damora Therapeutics, Inc. Common Stock's stock was trading at $23.01 at the start of the year. Since then, DMRA stock has increased by 8.1% and is now trading at $24.87.

How were Damora Therapeutics, Inc. Common Stock's earnings last quarter?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) released its quarterly earnings data on Thursday, November, 6th. The company reported ($2.36) earnings per share for the quarter.

When did Damora Therapeutics, Inc. Common Stock's stock split?

Damora Therapeutics, Inc. Common Stock's stock reverse split on Friday, August 30th 2024.The 1-25 reverse split was announced on Wednesday, August 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Damora Therapeutics, Inc. Common Stock?

Shares of DMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Damora Therapeutics, Inc. Common Stock own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Damora Therapeutics, Inc. Common Stock investors own include Realty Income (O), Oxford Square Capital (OXSQ), Plug Power (PLUG), AGNC Investment (AGNC), Aberdeen Total Dynamic Dividend Fund (AOD) and Abrdn Global Infrastructure Income Fund (ASGI).

Company Calendar

• Last Earnings: 11/06/2025
• Today: 5/05/2026
• Next Earnings (Estimated): 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DMRA
• Previous Symbol: NASDAQ:GLTO
• CIK: 1800315
• Web: galecto.com
• Phone: 45-7070-5210
• Fax: N/A
• Employees: 40
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Damora Therapeutics, Inc. Common Stock: $43.40
• High Price Target: $46.00
• Low Price Target: $40.00
• Potential Upside/Downside: +74.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($12.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$209.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -147.05%
• Return on Assets: -279.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.98
• Quick Ratio: 12.98

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($110.11) per share
• Price / Book: -0.23

Miscellaneous

• Outstanding Shares: 60,300,000
• Free Float: 53,995,000
• Market Cap: $1.50 billion
• Optionable: No Data
• Beta: 1.50